The Xpert HCV Viral Load Finger-Stick point-of-care test was accurate for detecting HCV RNA

2018 ◽  
Vol 169 (6) ◽  
pp. JC35
Author(s):  
Thomas Fekete
Keyword(s):  
Viral Load ◽  
Point Of Care ◽  
Hcv Rna ◽  
Point Of Care Test ◽  
Finger Stick

scholarly journals Time to Detection of Hepatitis C Virus Infection With the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis

2020 ◽  
Vol 221 (12) ◽  
pp. 2043-2049 ◽  
Author(s):  
Jason Grebely ◽  
Beth Catlett ◽  
Indika Jayasinghe ◽  
Heather Valerio ◽  
Behzad Hajarizadeh ◽  
...  
Keyword(s):  
Viral Load ◽  
Median Time ◽  
Point Of Care ◽  
Waiting Times ◽  
Hcv Rna ◽  
Rna Detection ◽  
Point Of Care Test ◽  
Rna Quantification ◽  
Observational Cohort ◽  
Time To Detection

Abstract Background Xpert HCV Viral Load Fingerstick assay (Xpert HCV VL FS) is a point-of-care test quantifying HCV RNA in <1 hour, enabling same-visit diagnosis and treatment. Methods This study evaluated time to HCV RNA detection using the Xpert HCV VL FS assay. Fingerstick whole-blood samples were collected from participants in an observational cohort in Australia. Results In May 2018–2019, 1468 participants were enrolled, 1426 had Xpert HCV VL FS testing performed, and 1386 had a valid result. HCV RNA was detected in 23% (325/1386). Among people with undetectable HCV RNA (n = 1061), median time to result was 57 minutes. Among people with detectable HCV RNA (n = 325), median time to HCV RNA detection was 32 minutes and 80% (261/325) had a detectable HCV RNA result in ≤40 minutes. Median time to HCV RNA detection was dependent on HCV RNA level. Conclusions A quicker HCV diagnosis could be achieved by monitoring the time when HCV RNA is first detected with the Xpert HCV VL FS test, rather than HCV RNA quantification, although the current platform does not allow for this. These findings could facilitate new strategies to reduce waiting times for an HCV diagnosis and improve linkage to treatment.

scholarly journals Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay

2018 ◽  
Vol 217 (12) ◽  
pp. 1889-1896 ◽  
Author(s):  
Francois M J Lamoury ◽  
Sahar Bajis ◽  
Behzad Hajarizadeh ◽  
Alison D Marshall ◽  
Marianne Martinello ◽  
...  
Keyword(s):  
Viral Load ◽  
Point Of Care ◽  
Finger Stick ◽  
Point Of Care Assay

scholarly journals Potential utility of the Genedrive point-of-care test for HCV RNA detection

Gut ◽  
2018 ◽  
Vol 68 (10) ◽  
pp. 1903-1904 ◽  
Author(s):  
Alba Llibre ◽  
Yusuke Shimakawa ◽  
Darragh Duffy
Keyword(s):  
Point Of Care ◽  
Hcv Rna ◽  
Potential Utility ◽  
Rna Detection ◽  
Point Of Care Test

Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study

2017 ◽  
Vol 2 (7) ◽  
pp. 514-520 ◽  
Author(s):  
Jason Grebely ◽  
Francois M J Lamoury ◽  
Behzad Hajarizadeh ◽  
Yasmin Mowat ◽  
Alison D Marshall ◽  
...  
Keyword(s):  
Cohort Study ◽  
Viral Load ◽  
Whole Blood ◽  
Point Of Care ◽  
Blood Samples ◽  
Load Point ◽  
Whole Blood Samples ◽  
Finger Stick ◽  
Point Of Care Assay

HCV-FiS (HEpatitis C Virus Finger-stick Study): HCV RNA point-of-care testing by GeneXpert in the setting of DAA therapy

2018 ◽  
Vol 68 ◽  
pp. S255-S256
Author(s):  
V. Calvaruso ◽  
F. Bronte ◽  
D. Ferraro ◽  
M.G. Bavetta ◽  
S. Petta ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Point Of Care ◽  
Hcv Rna ◽  
Point Of Care Testing ◽  
Finger Stick

HCV-FiS (HEpatitis C Virus Finger-stick Study): HCV RNA point-of-care testing by GeneXpert in the setting of DAA therapy

2018 ◽  
Vol 50 (1) ◽  
pp. 58
Author(s):  
F. Bronte ◽  
V. Calvaruso ◽  
D. Ferraro ◽  
S. Petta ◽  
B. Magro ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Point Of Care ◽  
Hcv Rna ◽  
Point Of Care Testing ◽  
Finger Stick

scholarly journals The Practicability of the Xpert HCV Viral Load Fingerstick Point-of-Care Assay in Primary Care Settings

Viruses ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2327
Author(s):  
David Petroff ◽  
Olaf Bätz ◽  
Katrin Jedrysiak ◽  
Jan Kramer ◽  
Thomas Berg ◽  
...  
Keyword(s):  
Primary Care ◽  
Viral Load ◽  
Primary Care Physicians ◽  
Point Of Care ◽  
Linkage To Care ◽  
Hcv Rna ◽  
Primary Care Settings ◽  
Hcv Screening ◽  
The Individual ◽  
Point Of Care Assay

Linkage to care presents one obstacle toward eliminating HCV, and the current two-step pathway (anti-HCV, followed by HCV-RNA testing) results in the loss of patients. HCV screening was tested in the primary care setting with the fingerstick Xpert HCV viral load point-of-care assay to analyze the practicability of immediate diagnosis. Anti-HCV (Cobas) and HCV-RNA (Cobas Amplicor version 2.0, only performed if anti-HCV was positive) were analyzed centrally as the gold standard. The Xpert assay was performed by 10 primary care private practices. In total, 622 patients were recruited. Five individuals (0.8%) were anti-HCV positive, and one was HCV-RNA positive. The Xpert test was valid in 546/622 (87.8%) patients. It was negative in 544 and positive in 2 cases, both of whom were anti-HCV negative. The HCV-RNA PCR and the Xpert test were both negative in 4/5 anti-HCV-positive cases, and the individual with HCV-RNA 4.5 × 106 IU/mL was not detected by the Xpert test. Primary care physicians rated the Xpert test practicability as bad, satisfactory, or good in 6%, 13%, and 81%, respectively, though 14/29 (48%) bad test ratings were assigned by a single practice. Despite adequate acceptance, interpretability and diagnostic performance in primary care settings should be further evaluated before its use in HCV screening can be recommended.

scholarly journals HDV Seroprevalence in HBsAg-Positive Patients in China Occurs in Hotspots and Is Not Associated with HCV Mono-Infection

Viruses ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 1799
Author(s):  
Imme Roggenbach ◽  
Xiumei Chi ◽  
Florian A. Lempp ◽  
Bingqian Qu ◽  
Lisa Walter ◽  
...  
Keyword(s):  
High Risk ◽  
Drug Users ◽  
Point Of Care ◽  
Epidemiological Data ◽  
University Hospital ◽  
Hospital Environment ◽  
Hcv Rna ◽  
Metropolitan Regions ◽  
Point Of Care Test ◽  
Hepatitis Delta Antigen

HDV infection causes severe liver disease, the global health burden of which may be underestimated due to limited epidemiological data. HDV depends on HBV for infection, but recent studies indicated that dissemination can also be supported by other helper viruses such as HCV. We used a rapid point-of-care test and an ELISA to retrospectively test for antibodies against the Hepatitis Delta antigen (anti-HDV-Ab) in 4103 HBsAg-positive and 1661 HBsAg-negative, anti-HCV-positive sera from China and Germany. We found that the HDV seroprevalence in HBsAg-positive patients in China is limited to geographic hotspots (Inner Mongolia: 35/251, 13.9%; Xinjiang: 7/180, 3.9%) and high-risk intravenous drug users (HBV mono-infected: 23/247, 9.3%; HBV-HCV co-infected: 34/107, 31.8%), while none of the 2634 HBsAg carriers from other metropolitan regions were anti-HDV-Ab-positive. In Germany, we recorded an HDV seroprevalence of 5.3% in a university hospital environment. In a cohort of HBsAg-negative, anti-HCV-positive patients that were not exposed to HBV before (anti-HBc-negative), HDV was not associated with HCV mono-infection (Chinese high-risk cohort: 0/365, 0.0%; German mixed cohort: 0/263, 0.0%). However, 21/1033 (2.0%) high-risk HCV patients in China with markers of a previously cleared HBV infection (anti-HBc-positive) were positive for anti-HDV-Ab, with two of them being positive for both HDV and HCV RNA but negative for HBV DNA. The absence of anti-HDV-Ab in HCV mono-infected patients shows that HCV cannot promote HDV transmission in humans.

Sign in / Sign up

Export Citation Format

Share Document